Investors & Media

Corporate Profile

We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.

ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

  • February 21, 2023
    Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
  • November 30, 2022
    Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
  • November 10, 2022
    Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split


  • September 29, 2022 at 3:30 PM EDT

    Ladenburg Thalmann 2022 Healthcare Conference

    Read More
  • September 12, 2022 at 7:00 AM EDT

    H.C. Wainwright 24th Annual Global Investment Conference

    Read More

To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of life


To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy